Patents by Inventor Christopher A. Ziebenhaus

Christopher A. Ziebenhaus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • APOL1 inhibitors and methods of use
    Patent number: 11976067
    Abstract: Provided herein are compounds of formula (II): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, p, R1, R2, R3, L1, L2, L3, R4, X1, X2, X3, and X4 are as defined herein. Also provided are methods of preparing compounds of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods of inhibiting APOL1 and methods of treating an APOL1-mediated disease, disorder, or condition in an individual.
    Type: Grant
    Filed: January 17, 2023
    Date of Patent: May 7, 2024
    Assignee: Maze Therapeutics, Inc.
    Inventors: Patrick Sang Tae Lee, Todd Jonathan August Ewing, Adam Neil Reid, Christopher Joseph Sinz, Birong Zhang, Sarah M. Bronner, David John Morgans, Jr., Maarten Hoek, Victoria Anne Assimon, Chris Ziebenhaus, Alexander Wayne Schammel
  • SUBSTITUTED ENEOXINDOLES AND USES THEREOF
    Publication number: 20230183262
    Abstract: The present disclosure relates generally to certain ene-oxindole compounds, pharmaceutical compositions comprising thereof. Also disclosed are methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.
    Type: Application
    Filed: August 17, 2022
    Publication date: June 15, 2023
    Inventors: Evangelos Aktoudianakis, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Kristyna M. Elbel, Rao V. Kalla, Samuel E. Metobo, Scott A. Mitchell, Thao D. Perry, Scott P. Simonovich, Christopher A. Ziebenhaus
  • Substituted eneoxindoles and uses thereof
    Patent number: 11453681
    Abstract: The present disclosure relates generally to certain ene-oxindole compounds, pharmaceutical compositions comprising thereof. Also disclosed are methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: September 27, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Evangelos Aktoudianakis, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Kristyna M. Elbel, Rao V. Kalla, Samuel E. Metobo, Scott A. Mitchell, Thao D. Perry, Scott P. Simonovich, Christopher A. Ziebenhaus
  • PD-1/PD-L1 inhibitors
    Patent number: 11236085
    Abstract: Compounds and methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: February 1, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Zhimin Du, Michael Graupe, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Eric Q. Parkhill, Barton W. Phillips, Scott P. Simonovich, Peiyuan Wang, Jie Xu, Christopher A. Ziebenhaus
  • SUBSTITUTED ENEOXINDOLES AND USES THEREOF
    Publication number: 20200392153
    Abstract: The present disclosure relates generally to certain ene-oxindole compounds, pharmaceutical compositions comprising thereof. Also disclosed are methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.
    Type: Application
    Filed: May 21, 2020
    Publication date: December 17, 2020
    Inventors: Evangelos Aktoudianakis, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Kristyna M. Elbel, Rao V. Kalla, Samuel E. Metobo, Scott A. Mitchell, Thao D. Perry, Scott P. Simonovich, Christopher A. Ziebenhaus
  • PD-1/PD-L1 INHIBITORS
    Publication number: 20200157094
    Abstract: Compounds and methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
    Type: Application
    Filed: October 22, 2019
    Publication date: May 21, 2020
    Inventors: Zhimin Du, Michael Graupe, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Eric Q. Parkhill, Barton W. Phillips, Scott P. Simonovich, Peiyuan Wang, Jie Xu, Christopher A. Ziebenhaus